Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

Azpilikueta A, Bolaños E, Lang V, Labiano S, Aznar MA, Etxeberria I, Teijeira A, Rodriguez-Ruiz ME, Perez-Gracia JL, Jure-Kunkel M, Zapata JM, Rodriguez MS, Melero I.

Oncoimmunology. 2017 Sep 21;7(1):e1368605. doi: 10.1080/2162402X.2017.1368605. eCollection 2017.

PMID:
29296520
2.

CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.

Aznar MA, Labiano S, Diaz-Lagares A, Molina C, Garasa S, Azpilikueta A, Etxeberria I, Sanchez-Paulete AR, Korman AJ, Esteller M, Sandoval J, Melero I.

Cancer Immunol Res. 2018 Jan;6(1):69-78. doi: 10.1158/2326-6066.CIR-17-0159. Epub 2017 Nov 13.

PMID:
29133290
3.

Cellular immunotherapies for cancer.

Berraondo P, Labiano S, Minute L, Etxeberria I, Vasquez M, Sanchez-Arraez A, Teijeira A, Melero I.

Oncoimmunology. 2017 May 2;6(5):e1306619. doi: 10.1080/2162402X.2017.1306619. eCollection 2017. Review.

PMID:
28638729
4.

CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes.

Labiano S, Meléndez-Rodríguez F, Palazón A, Teijeira Á, Garasa S, Etxeberria I, Aznar MÁ, Sánchez-Paulete AR, Azpilikueta A, Bolaños E, Molina C, de la Fuente H, Maiso P, Sánchez-Madrid F, de Landázuri MO, Aragonés J, Melero I.

Oncoimmunology. 2017 Jan 19;6(4):e1283468. doi: 10.1080/2162402X.2017.1283468. eCollection 2017.

5.

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I.

Cancer Res. 2016 Oct 15;76(20):5994-6005. Epub 2016 Aug 22.

6.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Fusco JP, Aznar A, Inogés S, De Pizzol M, Allegretti M, Medina-Echeverz J, Berraondo P, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2016 Aug 1;22(15):3924-36. doi: 10.1158/1078-0432.CCR-15-2463. Epub 2016 Mar 8.

7.

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.

Labiano S, Palazón A, Bolaños E, Azpilikueta A, Sánchez-Paulete AR, Morales-Kastresana A, Quetglas JI, Perez-Gracia JL, Gúrpide A, Rodriguez-Ruiz M, Aznar MA, Jure-Kunkel M, Berraondo P, Melero I.

Oncoimmunology. 2015 Jun 24;5(1):e1062967. eCollection 2016.

8.

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, Rodriguez-Ruiz ME, Pio R, Montuenga LM, Melero I.

J Thorac Oncol. 2016 Apr;11(4):524-36. doi: 10.1016/j.jtho.2016.01.013. Epub 2016 Feb 1.

9.

Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.

Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M, Melero I.

Eur J Immunol. 2016 Mar;46(3):513-22. doi: 10.1002/eji.201445388. Epub 2016 Feb 9. Review.

10.

Functional expression of CD137 (4-1BB) on T helper follicular cells.

Alfaro C, Echeveste JI, Rodriguez-Ruiz ME, Solorzano JL, Perez-Gracia JL, Idoate MA, Lopez-Picazo JM, Sanchez-Paulete AR, Labiano S, Rouzaut A, Oñate C, Aznar A, Lozano MD, Melero I.

Oncoimmunology. 2015 May 29;4(12):e1054597. eCollection 2015 Dec.

11.

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

Sánchez-Paulete AR, Cueto FJ, Martínez-López M, Labiano S, Morales-Kastresana A, Rodríguez-Ruiz ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI, Sancho D, Melero I.

Cancer Discov. 2016 Jan;6(1):71-9. doi: 10.1158/2159-8290.CD-15-0510. Epub 2015 Oct 22.

12.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I.

Cancer Res. 2015 Sep 1;75(17):3466-78. doi: 10.1158/0008-5472.CAN-14-3510. Epub 2015 Jun 25.

13.

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.

Weigelin B, Bolaños E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A, Quetglas JI, Wagena E, Sánchez-Paulete AR, Chen L, Friedl P, Melero I.

Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112. Epub 2015 Jun 1.

14.

Immune response regulation in the tumor microenvironment by hypoxia.

Labiano S, Palazon A, Melero I.

Semin Oncol. 2015 Jun;42(3):378-86. doi: 10.1053/j.seminoncol.2015.02.009. Epub 2015 Feb 13. Review.

PMID:
25965356
15.

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.

Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, Labiano S, San-Segundo L, Rodriguez A, Aires-Mejia I, Rodriguez I, Escalante F, de Coca AG, Barez A, San Miguel JF, Melero I.

Leukemia. 2015 Oct;29(10):2110-3. doi: 10.1038/leu.2015.79. Epub 2015 Mar 17. No abstract available.

PMID:
25778100
16.

Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade.

Quetglas JI, Labiano S, Aznar MÁ, Bolaños E, Azpilikueta A, Rodriguez I, Casales E, Sánchez-Paulete AR, Segura V, Smerdou C, Melero I.

Cancer Immunol Res. 2015 May;3(5):449-54. doi: 10.1158/2326-6066.CIR-14-0216. Epub 2015 Feb 17.

17.

Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer.

Morales-Kastresana A, Labiano S, Gütgemann I, Melero I.

Oncoimmunology. 2014 Jan 16;3:e27812. eCollection 2014.

18.

Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I.

Curr Opin Immunol. 2014 Apr;27:89-97. doi: 10.1016/j.coi.2014.01.002. Epub 2014 Jan 28. Review.

PMID:
24485523
19.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

20.

Better performance of CARs deprived of the PD-1 brake.

Morales-Kastresana A, Labiano S, Quetglas JI, Melero I.

Clin Cancer Res. 2013 Oct 15;19(20):5546-8. doi: 10.1158/1078-0432.CCR-13-2157. Epub 2013 Sep 4.

21.

LIF, a Novel STAT5-Regulated Gene, Is Aberrantly Expressed in Myeloproliferative Neoplasms.

Salas EM, García-Barchino MJ, Labiano S, Shugay M, Pérez-Encinas M, Quinteiro C, García-Delgado M, Vizmanos JL, Novo FJ.

Genes Cancer. 2011 May;2(5):593-6. doi: 10.1177/1947601911420139.

22.

Uptake of water, sodium and glucose by the ductuli efferentes of the hamster "in vitro".

Montorzi NM, Labiano SA.

Acta Physiol Lat Am. 1970;20(2):135-9. No abstract available.

PMID:
5529389

Supplemental Content

Loading ...
Support Center